Written by Steven HansenThe U.S. new cases 7-day rolling average are 32.8 % LOWER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 8.5 % LOWER than the rolling average one week ago. Today s posts include:
Share this article
Share this article
BALTIMORE, May 25, 2021 /PRNewswire/ Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, today announced the dosing of the first and second participants in its COVID-19 vaccine Phase 1/2 Clinical Trial in Japan.
The vaccine, called EXG-5003, is an intradermally-injected, temperature-controllable, self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein.
Elixirgen Therapeutics Announces First Dosing of COVID19 Vaccine EXG-5003 in Phase 1/2 Trial at Fujita Health University
Akihiro Ko, CEO of Elixirgen Therapeutics, said We are pleased to begin our Phase 1/2 study for EXG-5003, which has been in development since March of 2020. There is an ongoing global need for COVID-19 vaccines, and we believe in the importance of contributing to the public health effort.
Mass inoculation of seniors starts in Tokyo, Osaka and elsewhere : The Asahi Shimbun asahi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asahi.com Daily Mail and Mail on Sunday newspapers.
Researchers investigate antibodies that best neutralize SARS-CoV-2 in COVID-19 patients
The COVID-19 pandemic has now claimed over 2 million deaths worldwide, and this number is only increasing. In response, health agencies have rolled out tests to diagnose and understand the disease.
Besides the now widely known PCR test, there is interest in serological (blood) tests that detect antibodies against SARS-CoV-2, the virus that causes COVID-19. These blood tests have considerable applications, from identifying blood donors with high levels of anti-SARS-CoV-2 antibodies, whose blood can be used for convalescent plasma therapy, to measuring vaccine effectiveness.
So, what are antibodies? These are proteins produced by the body s immune system to combat foreign proteins, such as the SARS-CoV-2 virus. Antibodies function by binding to a specific part of the virus that the immune system recognizes, called antigens. SARS-CoV-2 is composed of four major proteins, with two being highly
E-Mail
IMAGE: Scientists look to untangle the mysteries of antibodies specific to SARS-CoV-2, the virus that causes COVID-19, in search of better tests and possible cures view more
Credit: Fujita Health University
The COVID-19 pandemic has now claimed over 2 million deaths worldwide, and this number is only increasing. In response, health agencies have rolled out tests to diagnose and understand the disease. Besides the now widely known PCR test, there is interest in serological (blood) tests that detect antibodies against SARS-CoV-2, the virus that causes COVID-19. These blood tests have considerable applications, from identifying blood donors with high levels of anti-SARS-CoV-2 antibodies, whose blood can be used for convalescent plasma therapy, to measuring vaccine effectiveness.